Efficacy and safety of ledipasvir and sofosbuvir in patients with chronic hepatitis C
Not Applicable
- Conditions
- Patients with chronic hepatitis C virus infection
- Registration Number
- JPRN-UMIN000018561
- Lead Sponsor
- Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 2000
Inclusion Criteria
Not provided
Exclusion Criteria
1) Severe multisystem disease, Severe immnodeficiency 2) Patients with chronic renal failure or patients with hemodialysis 3) Contraindication to ledipasvir or sofosbuvir 4) Contraindication to ledipasvir and sofosbuvir
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sustained virologic response rate Safety Cumulative incidence of hepatocellular carcinoma
- Secondary Outcome Measures
Name Time Method The factor associated with sustained virologic response Emergence of drug-resistant virus The factor associated with incidence of hepatocellular carcinoma